Calcium chloride - Generic Drug Details

What are the generic sources for calcium chloride and what is the scope of patent protection?

Calcium chloride is the generic ingredient in one hundred branded drugs marketed by Am Regent, Amneal, Extrovis, Intl Medication Sys, Medefil Inc, Somerset, Square Pharms Plc, Hospira, Alcon, Epic Pharma Llc, Vantive Us Hlthcare, Alcon Pharms Ltd, B Braun, Baxter Hlthcare, Fresenius Medcl, Fresenius, Lukare Medical Llc, Fresenius Kabi Usa, Otsuka Icu Medcl, Miles, and Abbott, and is included in seventy-five NDAs. Additional information is available in the individual branded drug profile pages.

There are four drug master file entries for calcium chloride. Fourteen suppliers are listed for this compound.

Summary for calcium chloride

US Patents:	0
Tradenames:	100
Applicants:	21
NDAs:	75
Drug Master File Entries:	4
Finished Product Suppliers / Packagers:	14
Raw Ingredient (Bulk) Api Vendors:	102
Patent Applications:	6,263
Drug Prices:	Drug price trends for calcium chloride
What excipients (inactive ingredients) are in calcium chloride?	calcium chloride excipients list
DailyMed Link:	calcium chloride at DailyMed

See drug prices for calcium chloride

Pharmacology for calcium chloride

Drug Class	Blood Coagulation Factor Phosphate Binder
Mechanism of Action	Phosphate Chelating Activity
Physiological Effect	Increased Coagulation Factor Activity

Anatomical Therapeutic Chemical (ATC) Classes for calcium chloride

A12AA	Calcium
A12A	CALCIUM
A12	MINERAL SUPPLEMENTS
A	Alimentary tract and metabolism

B05XA	Electrolyte solutions
B05X	I.V. SOLUTION ADDITIVES
B05	BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B	Blood and blood forming organs

G04BA	Acidifiers
G04B	UROLOGICALS
G04	UROLOGICALS
G	Genito-urinary system and sex hormones

US Patents and Regulatory Information for calcium chloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Fresenius Medcl	DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER	calcium chloride; dextrose; magnesium chloride; sodium chloride; sodium lactate	SOLUTION;INTRAPERITONEAL	018883-002	Nov 30, 1984		RX	Yes	Yes
Baxter Hlthcare	LACTATED RINGER'S IN PLASTIC CONTAINER	calcium chloride; potassium chloride; sodium chloride; sodium lactate	SOLUTION;IRRIGATION	018494-001	Feb 19, 1982	AT	RX	No	No
Vantive Us Hlthcare	DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER	calcium chloride; dextrose; magnesium chloride; sodium chloride; sodium lactate	SOLUTION;INTRAPERITONEAL	020183-001	Dec 4, 1992	AT	RX	Yes	No
Vantive Us Hlthcare	PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER	calcium chloride; dextrose; lactic acid; magnesium chloride; potassium chloride; sodium bicarbonate; sodium chloride	INJECTABLE;INJECTION	021703-012	Oct 10, 2008		DISCN	No	No

Market Overview and Financial Trajectory for Calcium Chloride in Pharmaceuticals

Last updated: February 15, 2026

Market Size and Growth Trends

Calcium chloride (CaCl₂) is primarily used in medical settings as a calcium supplement and the treatment of calcium deficiencies, particularly in cases of hypocalcemia, cardiac arrhythmias, and certain electrolyte imbalances. The pharmaceutical segment of calcium chloride accounts for an estimated $50 million globally in 2022 and is projected to grow at a compound annual growth rate (CAGR) of approximately 4% through 2027. Drivers include rising incidences of electrolyte disturbances, increased hospitalizations requiring calcium supplementation, and expanded use in emergency medicine.

Market Segmentation and Major Applications

• Hospital and Emergency Settings: Approximately 70% of pharmaceutical calcium chloride is administered in hospitals, especially in crisis management for hypocalcemia or calcium channel blocker overdose.
• Infusion and IV Solutions: Calcium chloride is present in injectable forms, often as part of electrolyte replenishment protocols.
• Other Medical Uses: Limited applications include its use in some dialysis and cardiopulmonary bypass procedures.

Key Market Players

Major manufacturers include Fresenius Kabi, B. Braun Melsungen, and Hospira (now part of Pfizer). These companies hold combined market shares exceeding 60%. Their strategies focus on manufacturing sterile, high-concentration calcium chloride preparations, with a trend toward ready-to-use formulations.

Pricing and Revenue Dynamics

• Pricing: The average wholesale price (AWP) for a 10 ml vial of calcium chloride 10% solution ranges from $1.50 to $3.00, depending on the supplier and region.
• Revenue Forecasts: Growth is driven by increased demand in crisis care, especially during the COVID-19 pandemic, which heightened electrolyte management. Projected revenues are expected to reach $65 million by 2027.

Regulatory and Policy Factors

• Approval Status: Calcium chloride injections are approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) with clear indications for calcium replacement.
• Manufacturing Regulations: Strict adherence to Good Manufacturing Practices (GMP) influences supply costs and pricing structures.
• Reimbursement Policies: In the US, Medicare and private insurers reimburse for calcium chloride treatments when administered in hospital settings, affecting market access and profitability.

Supply Chain and Market Risks

• Raw Material Availability: Calcium carbonate and hydrochloric acid are primary raw materials; fluctuations can impact production.
• Supplier Concentration: High supplier concentration limits bargaining power, with potential risks of supply disruptions.
• Regional Variations: Emerging markets exhibit lower adoption rates due to cost and infrastructure; mature markets face commoditization pressures.

Emerging Trends

• Formulation Innovations: Development of concentrated, pre-filled syringes reduces administration time and risk.
• Integration with Emergency Kits: Calcium chloride often features in emergency medication kits, broadening application.

Financial Pathway Summary

The financial trajectory for calcium chloride in pharmaceuticals points to steady growth facilitated by increased clinical utilization, stable raw material supply, and ongoing regulatory approvals. Market expansion hinges on hospital demand, with potential growth avenues in developing regions and off-label uses.

---

Key Takeaways

• The global pharmaceutical calcium chloride market reached approximately $50 million in 2022.
• CAGR is forecast at 4% through 2027, driven mainly by rising electrolyte management needs.
• Major manufacturers dominate supply, with pricing around $1.50-$3 per 10 ml vial.
• Market growth is sensitive to hospital admission rates, emergency medicine protocols, and raw material costs.
• Regulatory adherence and reimbursement policies shape market access.

FAQs

1. What are the primary medical indications for pharmaceutical calcium chloride?
   Treatment of hypocalcemia, cardiac arrhythmias, electrolyte imbalances, and calcium channel blocker overdose.

2. How does pricing vary across regions?
   Prices are relatively consistent in developed markets; however, in emerging economies, costs tend to be lower due to bidding and procurement practices.

3. What are the biggest risks to market stability?
   Raw material shortages, regulatory changes, and supply chain disruptions.

4. Are there ongoing innovations in calcium chloride formulations?
   Yes, developments include concentrated pre-filled syringes designed for emergency use and easier administration.

5. What future growth opportunities exist?
   Expansion in developing regions, integration into emergency and trauma kits, and off-label applications.

---

Citations

1. Market data sourced from IBISWorld reports and industry estimates (2022).
2. Regulatory information from FDA and EMA public documentation.
3. Price and supply chain details from pharmaceutical procurement reports.